methods this phase i, open-label, dose-escalation study (clinicaltrials.gov: {"type":"clinical-trial","attrs":{"text":"nct00603538","term_id":"nct00603538"}}nct00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/ml) and paclitaxel (200 mg/m2) in japanese patients (n = 19) with chemotherapy-naïve, advanced nsclc.